Deutsche Bank AG Lowers Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Deutsche Bank AG reduced its position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 84.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,052 shares of the company's stock after selling 238,010 shares during the quarter. Deutsche Bank AG owned 0.07% of Larimar Therapeutics worth $170,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Fi3 FINANCIAL ADVISORS LLC grew its stake in shares of Larimar Therapeutics by 16.7% in the fourth quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company's stock worth $92,000 after acquiring an additional 3,411 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Larimar Therapeutics by 12.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock worth $137,000 after acquiring an additional 3,877 shares during the period. Bank of America Corp DE boosted its holdings in shares of Larimar Therapeutics by 8.1% in the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock worth $206,000 after buying an additional 3,980 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Larimar Therapeutics by 35.1% in the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock worth $75,000 after buying an additional 5,042 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Larimar Therapeutics in the fourth quarter worth approximately $25,000. 91.92% of the stock is currently owned by institutional investors.

Larimar Therapeutics Stock Up 8.9%

NASDAQ:LRMR traded up $0.22 during trading hours on Friday, hitting $2.68. 1,229,289 shares of the stock traded hands, compared to its average volume of 784,283. Larimar Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $11.20. The company has a market cap of $171.60 million, a price-to-earnings ratio of -2.33 and a beta of 0.79. The stock has a 50 day moving average price of $2.12 and a 200 day moving average price of $3.27.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Equities analysts forecast that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LRMR has been the topic of a number of research reports. Guggenheim reissued a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Robert W. Baird dropped their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Finally, HC Wainwright raised their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, March 25th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Larimar Therapeutics has a consensus rating of "Buy" and a consensus price target of $19.67.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.